<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486550</url>
  </required_header>
  <id_info>
    <org_study_id>ASK-1-2011</org_study_id>
    <nct_id>NCT01486550</nct_id>
  </id_info>
  <brief_title>Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy</brief_title>
  <acronym>VONE</acronym>
  <official_title>Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to investigate if hydroxyethyl starch (HES) is potential
      nephrotoxic and examine the effects on the circulation and kidneys during administration of
      HES during surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydroxyethyl starch (HES) is widely used in hospitals to maintain circulation in critically
      ill patients. In recent years studies have raised suspicion that HES is nephrotoxic. So far
      acute kidney injury has been diagnosed based on creatinine measurements, but new technology
      allows for earlier diagnosis using measurements of biomarkers in urine. The purpose of this
      project is to investigate HES's potential toxicity and effects on the circulation and kidneys
      using measurements of biomarkers specific for toxicity and for the sodium/water balance in
      the urine and by measurements of vasoactive hormones in the blood after administration of HES
      130/0.4
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient enrollment
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>u-NGAL</measure>
    <time_frame>2-4 hours</time_frame>
    <description>The main objective for the trial(only patients undergoing elective laparoscopic nephrectomy) is to measure the effect of hydroxyethyl starch on u-NGAL, which is a biomarker of nephrotoxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>u-Kim1 and u-LFABP</measure>
    <time_frame>2-4 hours</time_frame>
    <description>Another objective for the trial(only patients undergoing elective laparoscopic nephrectomy) is to measure the effect of hydroxyethyl starch on u-Kim1 and u-LFAPB, which are also biomarkers of nephrotoxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FENa, u-ENaCÎ², CH2O, u-AQP2,u-NCC, u-NK2CC</measure>
    <time_frame>2-4 hours</time_frame>
    <description>Secondarily to measure the effect of hydroxyethyl starch on the renal tubular transport of sodium and water during elective laparoscopic nephrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRC, p-Ang-II, p -Aldo, p-ANP,P-GDP, p-AVP, p-Endothelin</measure>
    <time_frame>2-4 hours</time_frame>
    <description>Thirdly to measure the effect of hydroxyethyl starch on vasoactive hormones during elective laparoscopic nephrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP, DBP, heartrate</measure>
    <time_frame>2-4 hours</time_frame>
    <description>Fourthly measure the effect of hydroxyethyl starch on central hemodynamics during elective laparoscopic nephrectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Voluven (Hydroxyethyl starch 130/0,4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride 9mg/ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voluven (Hydroxyethyl starch 130/0,4)</intervention_name>
    <description>7,5 ml/kg in the first hour and then 5 ml/kg minimum</description>
    <arm_group_label>Voluven (Hydroxyethyl starch 130/0,4)</arm_group_label>
    <other_name>Voluven</other_name>
    <other_name>Hydroxyethyl starch</other_name>
    <other_name>Venofundin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 9mg/ml</intervention_name>
    <description>7,5 ml/kg in the first hour and then 5 ml/kg</description>
    <arm_group_label>Sodium Chloride 9mg/ml</arm_group_label>
    <other_name>Isotone saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Males and females

          -  Indication for laparoscopic nephrectomy

        Exclusion Criteria:

          -  Blood donation within the last month

          -  Lack of wish to participate

          -  eGFR&lt; 15ml/min

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Sophie P. Kancir, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Holstebro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicinck forskningsafsnit, Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

